NCT02025907 - A Study to Evaluate the Efficacy and Safety of the Addition of Canagliflozin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and Sitagliptin | Biotech Hunter

Enrollment

218

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

September 30, 2015

Study Completion Date

September 30, 2015

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

Canagliflozin, 100 mg

One 100 mg capsule taken orally (by mouth) once daily.

DRUG

Canagliflozin, 300 mg

One 300 mg capsule taken orally (by mouth) once daily.

DRUG

Placebo

One placebo capsule taken orally (by mouth) once daily.

Trial Locations (57)

Unknown

Montgomery

Phoenix

Little Rock

Northridge

Norwalk

Rancho Cucamonga

San Ramon

Aurora

Denver

Littleton

Cooper City

Miami

North Miami Beach

Atlanta

Perry

Shawnee Mission

Marrero

Metairie

Metarie

Rockville

Jackson

Picayune

St Louis

Nashua

Albuquerque

Albany

Arlington

San Antonio

Sugarland

Bountiful

Coffs Harbour

Freemantle

Geelong

Heidelberg

Herston

Melbourne

Merewether

Sherwood

Sydney

Wollongong

Brampton

Hawkesbury

Toronto

La Rochelle Cedex 1 Poitou-Cha

La Tronche

Nancy

Narbonne

Nice

Paris

Vénissieux

Freiburg im Breisgau

Fulda

Hamburg

Münster

Neuwied

Pirna

Speyer

All Listed Sponsors

lead

Janssen Research & Development, LLC

INDUSTRY